Abstract We have previously shown that agonists selective for the cannabinoid receptor 2 (CB2), including O-1966, in- 
Introduction
It has been well established that cannabinoids can modulate the function of the immune system. Cannabinoids mediate their actions on the immune system through two identified cannabinoid receptors, designated CB1 and CB2. CB1 is highly expressed on neurons in the central nervous system (Galiegue et al. 1995; Herkenham et al. 1991; Matsuda et al. 1990) and to a lesser extent on cells of the immune system and testes (Daaka et al. 1996; Galiegue et al. 1995; Waksman et al. 1999) . CB2 is primarily expressed on cells of the immune system (Galiegue et al. 1995; Munro et al. 1993) , including activated microglia, (Murikinati et al. 2010 ) and sparsely on neurons (Gong et al. 2006) , and thus has emerged as a possible target for immunomodulation. There is now a significant body of research showing that activation of CB2 largely suppresses the action of leukocytes (Basu and Dittel 2011) . The CB2 receptor has been found to be important in the attenuation of several inflammatory and autoimmune disease models in rodents, including Experimental Autoimmune Encephalitis (EAE), which is a mouse model of multiple sclerosis, (Maresz et al. 2007; Zhang et al. 2009b) , ischemic/perfusion injury following an induced stroke (Ni et al. 2004; Zhang et al. 2007 Zhang et al. , 2009a , inflammatory bowel disease (Storr et al. 2008 (Storr et al. , 2009 ), Crohn's disease (Wright et al. 2008) , inflammatory autoimmune diabetes (Li et al. 2001) , spinal cord injury (Baty et al. 2008) , sepsis (Tschöp et al. 2009 ), autoimmune uveoretinitis (Xu et al. 2007) , osteoporosis (Ofek et al. 2006) and systemic sclerosis (Servettaz et al. 2010) . In the present studies, a CB2-selective agonist was tested as a potential therapeutic treatment to prevent graft rejection and graft-versushost disease using the widely accepted Mixed Lymphocyte Reaction (MLR) as an in vitro correlate of the immune reactivity to a transplant. This application of CB2-selective agonists has been suggested (Nagarkatti et al. 2010 ), but has not been previously tested experimentally, with the exception of a report from our laboratory (Robinson et al. 2013) . Rejection of grafts is primarily mediated by alloreactive T-cells (Heeger 2003) . Therefore, most current maintenance protocols for immunosuppressive anti-rejection therapies use compounds that inhibit T-cells, including the calcineurin inhibitors, tacrolimus (FK506) and cyclosporine (Anonymous 2012) . However, these medications have serious side effects, such as nephrotoxicity, post-transplant diabetes mellitus, hypertension, neurotoxicity, and hyperlipidemia (Jose 2007) . Improved therapeutic agents with decreased toxicity are needed for use alone or in combination with existing therapies given at reduced doses.
T-cells have been reported to be sensitive to inhibition by CB2-selective cannabinoid agonists under several experimental conditions, as evidenced by decreased production of cytokines (IL-2 and IFN-γ), by inhibition of migration of T-cells to inflammatory stimuli, and by inhibition of proliferation of Tcells (Börner et al. 2009; Cencioni et al. 2010; Coopman et al. 2007 ; Ghosh et al. 2006; Maresz et al. 2007; Robinson et al. 2013) . Previous work from our laboratory demonstrated that the CB2-selective agonists JWH-015 and O-1966 inhibited the murine MLR (Robinson et al. 2013) . The inhibition was via the CB2 receptor, as shown using cannabinoid receptor selective antagonists and spleen cells of mice with a genetic deficiency in this receptor (CB2R k/o). Additional results showed that these agonists acted primarily on CD3 + T-cells, rather than on CD11b + accessory cells, as exposure of CD3 + cells to these compounds completely inhibited their action in a reconstituted MLR, while exposure of CD11b + cells resulted in partial suppression. Further, proliferation of purified T-cells by anti-CD3 and anti-CD28 antibodies was inhibited. T-cell function was decreased by CB2-selective agonists, as an ELISA of MLR culture supernatants revealed IL-2 release was significantly reduced in the cannabinoid treated cells. These effects were not due to the induction of apoptosis, as cultures treated with the CB2 agonists did not exhibit increased levels of caspases or fragmented DNA measured by the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Current studies explored mechanisms by which the CB2-selective agonist O-1966 suppresses T-cells in the MLR. It was found that this cannabinoid increased Treg cells and IL-10 in MLR cultures, and down-regulated CD40 ligand, CyclinD3, and the transcription factors, NF-κB and NFAT, as well as decreasing CD4 expression. Together, these data show that a CB2-selective agonist can suppress T-cells by inhibiting certain parameters of their activation, while promoting an immunosuppressive Treg phenotype, and thus support the potential of this class of compounds as useful therapeutic agents to prolong graft survival in transplant patients.
Materials and Methods

Mice
Six week-old, specific pathogen-free C3HeB/FeJ and C57BL/ 6 J female mice were purchased from Jackson Laboratories (Bar Harbor, Maine). Founder CB2 receptor deficient (CB2R k/o) mice, on a C57BL/6 J background (Buckley et al. 2000) were obtained from the National Institutes of Health (Bethesda, MD) and bred in the Animal Core of the Center for Substance Abuse Research, P30 Center for Excellence, at Temple University School of Medicine Central Animal Facility. All animal experiments were performed in accordance with the guidelines of the Temple University Animal Care and Use Committee.
Compounds
O-1966 (CB2-selective agonist) was a generous gift from Anu Mahadevan (Organix, Woburn, MA). O-1966 was supplied as crystals and stored at -20°C and dissolved in absolute ethanol before each use. This solution was added drop-wise to the culture medium, RPMI-1640, used for the assay to obtain the desired concentration.
One-way Mixed Lymphocyte Reaction (MLR)
Mice were sacrificed and their spleens aseptically removed. Single cell suspensions were obtained by passing spleens through nylon mesh bags (Sefar Inc., Depew, NY) in RPMI-1640 with 5 % fetal bovine serum (FBS) containing 50 μM 2-mercaptoethanol (2-Me), and 100 U/ml penicillin and streptomycin sulfate. All reagents were purchased from Gibco Life Technologies (Carlsbad, CA), with the exception of FBS, which was purchased from HyClone Laboratories (Logan, UT). Red blood cells were lysed by hypotonic shock for 10 s with sterile water. Responder spleen cells from C57BL/ 6 mice were resuspended in RPMI with 10 % FBS, 50 μM 2-Me, and 100 U/ml penicillin and streptomycin sulfate. Splenocytes from C3HeB/FeJ were similarly prepared to serve as the stimulator cells, but they were inactivated by treatment with 50 μg/ml of mitomycin C for 20 min at 37 o C. Both responder and stimulator cells were resuspended to the desired concentration using a Beckman cells from cultures were resuspended in 1 ml PBS and incubated for 30 min at room temperature with 1 μl Dead Cell Stain. Cells were washed twice, resuspended in staining buffer and analyzed using an LSRII (BD Biosciences, San Jose, CA) and analyzed with FACSDiva™ software (BD Biosciences).
Fluorescence Activated Cell Sorting (FACS)
Splenocytes were resuspended in staining buffer (PBS containing 1 % BSA, Sigma, St. Louis, MO). Cells were incubated with 1 μg/10 6 cells 2.4G2 antibody specific for Fcγ III/II receptor (BioLegend, San Diego, CA) at 4°C for 5 min to prevent nonspecific binding. Cells were then stained with 1 μl/10 6 cells LIVE/DEAD ® Dead Cell Stain (Molecular Probes, Inc) and incubated for 30 min on ice with 1 μl Dead Cell Stain. For positive selections, cells were incubated with 0.5 μg/10 6 cells of fluorophore-conjugated anti-mouse CD3ε, CD4, or CD8 (BioLegend) for 30 min on ice. Cells were then washed twice with sorting buffer: PBS containing 0.1 % BSA (Sigma), resuspended in sorting buffer to a concentration of 4×10 7 cells/ml and sorted using the FACSAria™ system (BD Biosciences). For negative selection of T-cells, cells were prepared as above, but incubated with 0.5 μg/10 6 cells of fluorophore-conjugated rat anti-mouse CD11b (BioLegend) and 0.5 μg/10 6 cells of fluorophore-conjugated rat antimouse CD45R (B220) (Molecular Probes) for 30 min on ice, sorted with the FACSAria™ system (BD Biosciences), and collecting the double negative population.
In Vitro T-Cell Activation 96 well microplates were coated with 0.5 μg/well of LEAF™ Purified anti-mouse CD3ε (BioLegend) and incubated for 2 h at 37°C. Wells were washed to remove unbound antibody. C57BL/6 J splenocytes were sorted by flow cytometry as described above and CD3 + T-cells were negatively selected. 2x10 5 cells were added to each well and incubated at 37 o C for 30 min. Following incubation, 0.4 μg soluble LEAF™ Purified anti-mouse CD28 (BioLegend) was added to each well for a final concentration of 2 μg/mL. Cultures were incubated for 48 h at 37°C, pulsed with 1 μCi/well [ 3 H]-thymidine, and harvested 18 h later, and radioactive uptake measured by liquid scintillation counting using a Packard 1900 TR liquid scintillation counter.
Transcription Factor Analysis
Splenocytes from CB2R k/o mice or wild-type mice were treated for 3 h with O-1966 before activation with anti-CD3 and anti-CD28 antibodies, and then incubated for 18 h. 8.8× 10 6 cells per treatment group were harvested and nuclear protein was extracted using a Nuclear Extract Kit (Active Motif, Carlsbad, CA), following the provided protocol. Protein levels were quantified using the Bradford reagent (Sigma) and absorbance read on a POLARstar Omega microplate reader (BMG LABTECH, Offenburg, Germany). Protein levels were adjusted to 2.5 μg/μl and stored at -80°C until use. Levels of activated NFAT were measured using a TransAM™ NFATc1 Transcription Factor Assay Kit (Active Motif) according to manufacturer's protocol. Briefly, 20 pmol (in 2 μl) of oligonucleotide containing the consensus sequence for NFAT and 50 μl containing 5 μg of nuclear extract were used in the assay in the provided 96-well assay plate. 100 μl mouse antiNFATc1 antibody was added to the bound transcription factor followed by the addition of 100 μl of anti-mouse horse radish peroxidase (HRP)-conjugated antibody and the provided reagents for a colorimetric reaction. The optical density was determined using a POLARstar Omega microplate reader (BMG LABTECH). NF-κB levels were measured using a TransAM™ Flexi NFκB p50 Transcription Factor Assay Kit (Active Motif) according to manufacturer's protocol. The protocol was the same as described above, except using 1 pmol (in 1 μl) of biotinylated oligonucleotide containing the consensus sequence for NFκB combined with 50 μl containing 5 μg of nuclear extract. Bound transcription factor was detected with 100 μl rabbit anti-NFκB p50 and 100 μl anti-rabbit HRPconjugated antibody.
mRNA Expression Analysis
Cells were harvested from the MLR 18 h into culture and total RNA was extracted using an RNeasy® Mini Kit (Qiagen, Valencia, CA) according to the provided protocol. RNA concentration and purity was checked with a NanoDrop2000 (Thermo Fisher Scientific, Waltham, MA). RNA was then reverse transcribed to cDNA using the RT 2 First Strand Kit (Qiagen) following the provided protocol. cDNA was then analyzed using the RT 2 Profiler PCR Array for Mouse T-cell and B-cell Activation (Qiagen) on the Mastercycler ep realplex2 (Eppendorf, Hamburg, Germany). The changes in expression of several genes that showed≥4-fold changes were confirmed by individual quantitative PCR (qPCR) with gene-specific primers (200 nM forward primer and 200 nM reverse primer) (Invitrogen, Grand Island, NY) and 10 μl Power SYBR® Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) on the Mastercycler ep Realplex2 (Eppendorf). The relative quantification of experimental genes in comparison to the reference gene, β-Actin, was determined. The relative expression ratio was calculated based on the qPCR efficiency and the crossing points for the experimental genes and β-Actin transcripts.
Flow Cytometry
MLR cultures were harvested at various time points and washed with staining buffer, (PBS containing 1 % BSA, Sigma, St. Louis, MO). 1x10 6 cells in 1 ml of PBS were added to Falcon™ polystyrene round-bottom tubes (BD Biosciences) and stained with 1 μl of LIVE/DEAD ® Dead Cell Stain (Molecular Probes, Inc) for 30 min on ice. The cells were washed twice with staining buffer and resuspended in 50 μl of staining buffer. To prevent nonspecific binding, the cells were incubated with 1 μg of 2.4G2 antibody specific for Fcγ III/II receptor (BioLegend) at 4°C for 5 min. To determine the number of Treg cells, suspensions were then incubated with 0.5 μg of fluorophore conjugated rat anti-mouse CD3ε (BioLegend), rat anti-mouse CD4 (BioLegend), or isotype control for 30 min on ice, washed twice with staining buffer and resuspended in PBS with 2 % (w/v) paraformaldehyde (Sigma) on ice for 15 min. The cells were washed 3 times with PBS and resuspended in 1 ml PBS with 0.5 % (v/v) Tween 20 (Sigma), washed 3 times with staining buffer and resusupended in 100 μl staining buffer containing 0.5 μg rat anti-mouse Foxp3 or isotype control (BioLegend) at room temperature for 30 min. The cells were washed 3 times with staining buffer, resuspended in 400 μl staining buffer, and analyzed immediately on the LSRII cytometer (BD Biosciences) equipped with 488 nm, 405 nm, 640 nm and 355 nm lasers, and analyzed using FACSDiva software (BD Biosciences) and post-analyzed with FlowJo (Tree Star, Inc., Ashland, OR). Compensation for spectrum overlaps between fluorochromes was performed using FACSDiva software (or Flowjo software). To determine which cells were secreting IL-10, separate MLR cultures, after 48 h incubation, were treated with GolgiStop ® Protein Transport Inhibitor containing monensin (BD Biosciences) for at least 4 h at 37°C before harvesting. Cells were then harvested and washed in staining buffer, and stained with 1 μl of eFluor 780 Fixable Viability Stain (eBioscience) for 30 min at 4°C, then stained for surface markers with eFluor 450 labeled anti-mouse CD3ε, PE-Cy7 labeled anti-mouse CD45R (eBioscience, San Jose, CA), and BV605 labeled anti-mouse CD11b (BioLegend), as above. After washing in staining buffer, cells were fixed in 4 % paraformaldehyde solution (Sigma Chemical Co.) for 20 min at 4°C, and washed 2× in staining buffer. Cells were then resuspended in BD Perm/Wash ® buffer (BD Bioscience) for 15 min, pelleted by centrifugation, and resuspended in 50 μl of Perm/Wash ® buffer. Cells were then stained with APC labeled anti-mouse IL-10 (BD Biosciences) for 30 min at 4°C in the dark, and washed 2× with Perm/Wash ® buffer. Cells were resuspended in 400 μl staining buffer for flow cytometry using the LSRII and software as described above.
ELISA IL-10 levels in the MLR culture supernatant were determined using the Ready-Set-Go! ® reagent set (eBioscience, San Diego, CA). Costar ® 96 well flat bottom high affinity protein binding microplates (Corning Inc. Life Sciences, Tewksbury, MA) were coated overnight at 4°C with capture antibody specific for mouse IL-10. The rest of the assay and incubations were performed at room temperature. After 24 h in culture, the MLR supernatant was harvested and 100 μl/well was added into the prepared microplate and incubated for 2 h. After incubation, the wells were washed 5 times with wash buffer, PBS with 0.05 % (v/v) of Tween-20 (Sigma), to remove unbound antigen. Then 100 μl/well of capture biotin-conjugated antibody against mouse IL-10 was added and incubated for 1 h. The wells were then washed 5 times to remove unbound antibody and an Avidin-horseradish peroxidase (HRP) solution was added and incubated for 30 min. The wells were washed 5 times and 100 μl/well of Tetramethylbenzidine (TMB) substrate solution was added and incubated for 15 min, followed by addition of 50 μl/well of dilute hydrochloric acid stop solution. The optical density was determined using a POLARstar Omega microplate reader (BMG LABTECH, Offenburg, Germany).
Statistics
Two-sample (independent or paired) t-test was employed to compare two treatment groups or post vs. pre-treatment within one sample. In cases with more than two treatment groups, ANOVA was utilized for between group comparisons, where multiple testing p-values were adjusted using the Dunnett method. Normality assumption of the study endpoints was empirically examined and transformations such as log or square root were explored if evidence from the data did not support normality. The two-way ANOVA was also employed to test differences in outcome measurements across different groups when there were two treatment conditions involved as well as possible interactions between them. A p-value of 0.05 or less was considered to be statistically significant. SAS© software (version 9.3, Cary, NC) was used for all the data analyses reported here.
Results
A CB2-Selective Agonist Alters Gene Expression in T-Cells
Previously, we have shown that the CB2-selective agonist, O-1966, directly inhibits the proliferation of T-cells in the MLR and of purified T-cells activated by anti-CD3/CD28 antibodies (Robinson et al. 2013) . To examine a possible mechanism of this suppression, nuclear levels of the transcription factors NF-κB and NFAT were measured in the presence or absence of O-1966. Splenocytes from wild-type C57BL/6 mice or CB2 receptor knockout (CB2R k/o) mice were sorted by flow cytometry and T-cells were negatively selected (CD11b -B220 -). The T-cells were treated for 3 h with O-1966 or ethanol vehicle and then activated with anti-CD3 and anti-CD28 antibodies and incubated for 18 h. The cells were then harvested and nuclear proteins extracted. Levels of activated NF-κB and NFAT that were able to bind to their target promoters were measured using the TransAM® transcription factor ELISA kits for NF-κB p50 and NFATc1. Figure 1 shows that treatment of T-cells from wild-type mice with O-1966 significantly decreased levels of both transcription factors in a dose-related manner, with suppression observed at concentrations of the cannabinoid of 16 and 32 μM for NF-κB, and of 8 to 32 μM for NFAT, as compared to ethanol vehicle controls. Suppression of neither transcription factor was observed in cultures containing Tcells from CB2R k/o mice. Identical cultures run in parallel, were harvested at 18 h and tested to measure cell viability using a Live/Dead ® dead cell stain. No difference was observed in the number of dead cells between control and cannabinoid treated groups (data not shown).
To examine the effect of cannabinoids on the expression of genes involved in T-cell activation, an RT 2 Profiler™ PCR Array for T-cell and B-cell activation was used. C57BL/6 responder splenocytes were pretreated for 3 h with 32 μM O-1966 or ethanol vehicle before the addition of mitomycin C inactivated C3HeB/FeJ splenocytes. After 18 h, the cultures were harvested and purified by flow cytometry. The CD3 + Tcell population was collected and RNA extracted and analyzed. Figure 2 Figure 4b shows that treatment with 8, 16, and 32 μM of O-1966 resulted in a dose dependent decrease of the mean fluorescence intensity of CD4 expression on the cell surface. Further, when splenocytes from CB2R k/o mice were used, there was no change in CD4 fluorescence intensity when treated with similar doses of O-1966, demonstrating that the decreased expression in wild-type mice is CB2 mediated.
O-1966 Increases IL-10 Release in the MLR
The release of IL-10 in the MLR was examined to support the observed increase of IL-10 mRNA expression detected in the array. Culture supernatants were collected 24 h after the start of the MLR. Figure 5 shows that O-1966, in doses ranging from 8 to 32 μM, significantly increased IL-10 release in a dose-related manner, indicating that O-1966 promotes an increase in this anti-inflammatory cytokine. Furthermore, when splenocytes from CB2R k/o mice were used, O-1966 treatment did not increase IL-10 release, indicating that this effect is CB2 receptor dependent. 
Role of IL-10 in Suppression of Proliferation and Increase in Tregs from O-1966 Treatment
To assess the importance of increased IL-10 levels in the suppression of the MLR, cultures were treated with 2.5 or 5 μg/ml of anti-IL-10 antibody at T 0 and 24 h into the assay to deplete the released IL-10. Figure 7a shows that the addition of 5 μg/ml anti-IL-10 antibody gave approximately 50 % reversal of suppression induced by the 32 μM dose of O-1966. As IL-10 is reported to up-regulate Treg cells (Groux et al. 1997) , the effect of IL-10 depletion on the increase of the percentage of Tregs in the MLR by O-1966 was also assessed. MLR cultures were treated with 2.5 or 5 μg/ml anti-IL-10 at T 0 and 24 h, and cells harvested 48 h into the assay were stained and analyzed by flow cytometry for Tregs. Figure 7d shows that the addition of both 2.5 and 5 μg/ml anti-IL-10 antibody completely blocked the increase of CD4 The cell subset that was the source of IL-10 was probed using flow cytometry. After surface staining for CD3, CD45R or CD11b to detect T-cells, B-cells and macrophages, intracellular staining for this cytokine was carried out. As shown in 
Discussion
Recipients of allogeneic transplants must maintain lifelong immunosuppressive therapies to prevent rejection. Immunosuppressive agents most often target T-cells (Heeger 2003) . Once alloreactive CD4 + T-cells are primed, they can differentiate into a pro-inflammatory type-1 phenotype, upregulating CD40L and CD28 and releasing IL-2 and IFN-γ to activate cytotoxic CD8 + T-cells, which subsequently injure the graft (Lee et al. 1994) or directly mediate graft destruction (Grazia et al. 2010; Pietra et al. 2000) . While most CD8 + Tcells require CD4 + T-cells for activation, some CD8 + T-cells can be primed independently by dendritic cells in a process called licensing (Albert et al. 1998; Buller et al. 1987; Matzinger and Bevan 1977) . Even with continuous antirejection therapy, eventually many grafts are ultimately rejected. Therefore, new therapeutic approaches are necessary and could potentially be given alone or in combination with current standard treatments, in an effort to lower the required doses of tacrolimus and cyclosporine.
The studies presented in this paper provide pre-clinical evidence that a CB2-selective agonist is a potential treatment to prevent graft rejection, as it is able to decrease certain parameters of T-cell activation while increasing two potent antiinflammatory parameters, IL-10 and Treg cells. Previously we have shown that CB2 expression increased 7-fold in the MLR and CB2-selective agonists inhibit the MLR with decreased IL-2 release (Robinson et al. 2013) . Current studies explored additional mechanisms by which the CB2-selective agonist O-1966 suppresses T-cells. It was found that this CB2 agonist decreased levels of the active nuclear forms of NF-κB and NFAT in T-cells of wild-type mice, but not of CB2R k/o mice. In addition, O-1966 treatment significantly decreased mRNA expression for CD40L, a co-stimulatory molecule (van Kooten and Banchereau 2000) , and Cyclin D3, a positive regulator for the transition from G 1 to S phase during cell division (Ando et al. 1993 ). This compound also caused a dose-related decrease of CD4 expression on wild-type T-cells in the MLR, but not on T-cells lacking CB2. The high doses of CB2-selective agonists needed in vitro have been previously addressed (Robinson et al. 2013) . It has been established that serum in cell cultures interferes with cannabinoid activity, so that there may be a poor correspondence between in vitro and in vivo doses (Klein et al. 1985; Nahas et al. 1977) . Several groups have used CB2 selective agonists in vivo to reduce immune mediated effects in mouse models of spinal cord injury (Adhikary et al. 2011; Baty et al. 2008) , stroke (Murikinati et al. 2010; Zhang et al. 2009a, b) , inflammatory bowel disease (Cencioni et al. 2010) , colitis (Storr et al. 2009 ), and sepsis (Tschöp et al. 2009 ). These agents have been found to have efficacy at doses in the range of 1 to 20 mg/kg. We have also found that O-1966 has efficacy in retarding graft rejection at 5 mg/kg (unpublished observations). Thus, the MLR would seem to predict in vivo efficacy, in spite of the rather high doses of cannabinoid required in vitro.
A number of similar observations have been made using THC, but not in the MLR (Börner et al. 2009; Lu et al. 2009; Ngaotepprutaram et al. 2012; Zhu et al. 2000) . However, in O-1966 versus vehicle) previous investigations it was not determined whether the Δ 9 -THC was exerting its effects via the CB1 or the CB2 receptor. Δ 9 -THC binds to both CB1 and CB2 receptors, and T-cells and antigen-presenting cells express both receptors. In the present manuscript we extend these results and show that signaling through the CB2 receptor by a CB2-selective agonist is sufficient to achieve the same results. The CB2 agonists have a clear advantage over Δ
9
-THC in that they should not produce major psychoactive effects due to the low expression of the CB2 receptor on neurons (Galiegue et al. 1995) . O-1966 , administered intravenously in doses up to 30 mg/kg, did not produce any effects in behavioral analyses used to assess the psychoactive effects of cannabinoids (Zhang et al. 2007) . Recently, however, there is some evidence that these compounds may have some subtler neuronal functions (Onaivi et al. 2008a, b; Xi et al. 2011) .
There is ample evidence in the literature to suggest preventing T-cell activation would provide sufficient protection against graft rejection (Heeger 2003) , including the mechanisms induced by O-1966 reported here. Blocking the transcriptional activity of NFAT or NF-κB abrogates allograft rejection (Finn et al. 2001; Ueno et al. 2011) . The inhibition of calcineurin by tacrolimus and cyclosporine, the standard antirejection drugs, blocks the translocation of the cytosolic component of NFAT to the nucleus (Ho et al. 1996) . NFAT has been shown to be involved in the regulation of expression of CD40L on T-cells (van Kooten and Banchereau 2000) . CD40L is expressed predominantly on activated CD4 + cells and induces an activating response when it binds to its receptor, CD40, which is expressed on a variety of cell types (Peng et al. 2001) . Particularly important for transplant rejection, CD40-CD40L interactions have been shown to mediate the delivery of T-cell help by T helper CD4 + T-cells expressing CD40L to the CD40 + dendritic cells, which then activate CD8 + T-cells into killers (Ridge et al. 1998) . CD40L expression is increased 4-fold in cases of acute rejection, and antibodies against CD40L have been found to be protective in mouse and monkey models of transplantation, including renal, pancreas, and skin allografts (Daoussis et al. 2004) . Unfortunately, studies testing the effects of anti-CD40L blockade in humans were halted because of the development of thromboembolic phenomena (Kawai et al. 2000) . Therefore, treatments that decrease the expression of CD40L may obtain the same immunosuppression without the adverse effects of the anti-CD40L antibodies. The 4-fold decrease in CD40L expression on T-cells in the MLR reported here may provide significant protection against graft rejection.
Additionally, O-1966 treatment reduced expression levels of CD4 on the cell surface. Through its interaction with class II major histocompatibility complex (MHC) on antigen presenting cells (APC), CD4 affects the activation and function of both T-cells and APC through the stabilization of TCR and APC interactions and subsequent MHC class II signaling (AlDaccak et al. 2004; Miceli and Parnes 1991) . Moreover, CD4 directly participates in T-cell signal transduction (Miceli and Parnes 1991) through the recruitment of the leukocytespecific protein tyrosine kinase (Lck) (Li et al. 2004; Straus and Weiss 1992) . Recently, treatment with Δ 9 -THC or the CB2-selective agonist, JWH-015, was shown to block the dephosphorylation of an inhibitory region of Lck that prevents autophosphorylation and subsequent initiation of TCR signaling in primary human T-cells and Jurkat T-cells activated with anti-CD3/ CD28 antibodies (Börner et al. 2009 ). Whether CB2 agonists block T-cell activation in the MLR by reducing CD4 surface expression, thereby decreasing CD4 and MHC class II interactions or by directly dampening TCR signaling will be investigated further.
In addition to blocking T-cell activation, O-1966 also induced a potent suppressive response in the MLR, through enhanced IL-10 release, which has been shown to inhibit the MLR (Bejarano et al. 1992) , and also by increasing the percentage of Tregs. It has previously been shown that nonselective CB1/CB2 cannabinoids increased IL-10 and Tregs levels (Arevalo-Martin et al. 2012; Hegde et al. 2008; Klein et al. 2000; Lu et al. 2009; McKallip et al. 2005; Smith et al. 2000) . The current results extend the published observations with nonselective cannabinoids by using CB2-selective compounds. The increased number of Tregs in O-1966 treated MLR cultures was completely blocked by the addition of neutralizing anti-IL-10 antibodies. This is consistent with a study by Groux et al. that showed IL-10 was able to induce Tregs, which then overproduced IL-10 and suppressed the proliferation of CD4 + T-cells in response to antigen (Groux et al. 1997) . The observation linking the action of a CB2 agonist with the interplay of IL-10 and Tregs is novel. It is worth noting that we have previously shown that IL-2 is depressed in MLR cultures treated with CB2 agonists (Robinson et al. 2013) . Others have shown a similar CB2-induced decrease in IL-2 in an assay measuring activation of antigen-specific Tcells (Maresz et al. 2007 ). There is a conundrum in that IL-2 is reportedly needed for induction of Tregs (Davidson et al. 2007; Tone et al. 2008 ). While there is no ready explanation for this seeming contradiction, it may be that the decrease in IL-2 is gradual over the first 24 h of the MLR assay, so that there is initially sufficient cytokine to allow Treg induction.
The results presented here also demonstrate that both T-cells and B-cells harvested from the MLR contain significant amounts of intracellular IL-10. We were unable to determine if the T-cell population that was IL-10 positive was the Treg subset, as there was interference between the intracellular stains for Foxp3 and IL-10. The unexpected observation of IL-10 secreting B-cells suggests that the CB2 agonist may have the capacity to induce B10 cells with immunosuppressive capacity (Candando et al. 2014; Rahim et al. 2005; Rosser et al. 2014 ). This finding is of interest because it has been reported that B-cells are needed for emergence of Treg cells (Sun et al. 2008; Tadmor et al. 2011) . Further investigation will be needed to purify and test the functional and phenotypic characteristics of this cell population generated in the MLR.
The induction of IL-10 and Tregs by a CB2-selective agonist make this class of compounds particularly promising, because the generation of Tregs could increase the likelihood of graft survival while decreasing the need for long-term immunosuppressive therapies. IL-10 has been shown to inhibit antigen presentation, antigen-specific T-cell proliferation, and decrease Th1 cytokine production (Fiorentino et al. 1991; Mitra et al. 1995) . Blocking the activity of IL1 0 in vivo in transplantation models diminished the survival of grafts (Kingsley et al. 2002; McMurchy et al. 2011 ) and was essential for the induction and maintenance of Tregs (Wood et al. 2012) . Indeed, following transplantation in both humans and animals, the presence of Tregs in the spleen, draining lymph notes, and at the site of the allograft, closely correlated with graft acceptance (Wood et al. 2012) . Together, the present data show that CB2 activation can suppress T-cells in the MLR by blocking T-cell function while favoring the induction of Tregs. We have also shown that in vivo administration of O-1966 at 5 mg/kg every other day for 14 days retards skin graft rejection in mice, depresses the response of spleen cells from treated mice placed ex vivo in an MLR assay, and induces Tregs in spleens (manuscript in preparation). Overall, the results presented in this paper support CB2-selective agonists as a new class of compounds to prevent graft rejection and graft-versus-host disease in patients, and potentially as a new class of immunosuppressive and anti-inflammatory drugs for a variety of other immune mediated conditions.
